Cardiff Oncology Inc (NASDAQ:CRDF) does about 1.15M shares in volume on a normal day but saw 1026159 shares change hands in the recent trading day. The company now has a market cap of 246.15M USD. Its current market price is $3.70, marking a decrease of -4.15% compared to the previous close of $3.86. The 52 week high reached by this stock is $5.64 whilst the lowest price level in 52 weeks is $2.01.
The consensus objective for the share price is $14.40, suggesting that the stock has a potential upside of 74.31% over the period.
FactSet Research has provided data showing that 1 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on September 06, 2024 when Craig Hallum initiated the stock to “Buy” and issued a price target of $8. Robert W. Baird initiated its price target at $19.
The current price level is 5.59%, 21.40%, and 12.86% away from its SMA20, SMA50, and SMA200 respectively, with the CRDF price moving below the 50-day SMA on current market day. Cardiff Oncology Inc (CRDF) stock is down -13.95% over the week and 31.67% over the past month. Its price is -14.75% year-to-date and 30.74% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.2 and -0.85 for whole year. Expected sales for next quarter are $100k, which analysts say will come at $389.57k for the current fiscal year and next year at $285.71k. In addition, estimates put the company’s current quarterly revenue at an average of $100k.
To reach the target analysts have set, the stock logically needs to grow 74.31 percent from here.
The company has a return on investment of -68.35% and return on equity of -74.15%. The beta has a value of 1.57. Price to book ratio is 3.47 and price to sales ratio is 417.20.
